Bevacizumab in combination with irinotecan and capecitabine as first line treatment for MCRC efficacy and safety.
Naslov
Bevacizumab in combination with irinotecan and capecitabine as first line treatment for MCRC efficacy and safety.
Identifikator
/unibl/sci/idNaucniRad:7053
Tip
Pronađite slične unoseConference Paper
Datum
Pronađite slične unose2014-06
Bibliografski citat
S. Jungić, G. Kecman Malčić, I. Rakita, D. Jovanović, R. Gajanin, Z. Marić, T. Biljana, Z. Gojković, Bevacizumab in combination with irinotecan and capecitabine as first line treatment for MCRC efficacy and safety., Annals of Oncology 2014; 25 (Supplement 2):, pp. 68 - 68, Jun, 2014
Početna stranica
68
Krajnja stranica
68
Prezentovano
ESMO 16th World Congress on Gastrointestinal Cancer
Je dio
Annals of Oncology 2014; 25 (Supplement 2):
Lista autora
Position: 24131 (31 views)